By Amirah Al Idrus | Fierce Biotech | November 14, 2019
Dewpoint Therapeutics, the biotech working to drug biomolecular condensates, has struck its first big deal. It’s teaming up with Bayer on new treatments for a pair of neglected fields: heart disease and women’s health.
The multiyear deal could be worth up to $100 million, but the duo did not break that figure down further. They will put Dewpoint’s condensates technology and Bayer’s small molecule library and R&D expertise to work, with the German pharma picking up the option to license a “specified number” of programs from the deal.
